Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [21] Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study (vol 28, pg 765, 2021)
    Iguchi, T.
    Kimura, G.
    Fukasawa, S.
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (10) : 1079 - 1079
  • [22] Pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Randomized double-blind phase III KEYNOTE-991 study
    Gratzke, C. J.
    Ozguroglu, M.
    Peer, A.
    Sendur, M. A. N.
    Retz, M.
    Goh, J. C. H.
    Loidl, W. C.
    Jayram, G.
    Byun, S-S.
    Kwak, C.
    Kwiatkowski, M.
    Kopp, R. Manneh
    Limon, J. C. Vazquez
    Penagos, J. F. Escobar
    De Giorgi, U. F. F.
    Trindade, K. M. D.
    Niu, C.
    Liu, Y.
    Poehlein, C. H.
    Rodriguez, J. M. Piulats
    ANNALS OF ONCOLOGY, 2023, 34 : S957 - S958
  • [23] Post hoc analysis of East Asian subpopulation in arches, a phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (MHSPC)
    Iguchi, Taro
    Pu, Yeong-Shiau
    Kimura, Go
    Byun, Seok-Soo
    Ha, Hong Koo
    Hong, Jun Hyuk
    Li, Jian-Ri
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2020, 27 : 96 - 97
  • [24] HSD3B1 genotype and outcomes in metastatic hormone-sensitive prostate cancer with androgen deprivation therapy and enzalutamide: ARCHES
    Sharifi, Nima
    Azad, Arun A.
    Patel, Mona
    Hearn, Jason W. D.
    Wozniak, Michele
    Zohren, Fabian
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    CELL REPORTS MEDICINE, 2024, 5 (08)
  • [25] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses EDITORIAL COMMENT
    Smoragiewicz, Martin
    Emmenegger, Urban
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1370 - 1370
  • [26] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
    Todenhoefer, Tilman
    Smith, Matthew R.
    Hussain, Maha
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alekseev, Boris
    Pino, Alvaro Montesa
    Ye, Dingwei
    Parnis, Francis
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 110 - 110
  • [27] KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)
    Gratzke, Christian
    Gratzke, Christian
    Gratzke, Christian
    Niu, Cuizhen
    Poehlein, Christian
    Burgents, Joseph
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A211 - A211
  • [28] Enzalutamide and Docetaxel in Combination With Androgen Deprivation for Men With Metastatic Hormone-Sensitive Prostate Cancer: ENZADA, a Phase II Trial
    Burgess, Earle F.
    Grigg, Claud M.
    Boselli, Danielle
    Symanowski, James T.
    Golshayan, Alireza
    Graham, David L.
    Osei-Boateng, Kwabena
    Gavini, Nagajyothi
    Zhu, Jiang
    Brown, Landon C.
    Norek, Sarah
    Begic, Xhevahire J.
    Raghavan, Derek
    CLINICAL GENITOURINARY CANCER, 2025, 23 (02)
  • [29] Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer A Randomized Clinical Trial
    Vaishampayan, Ulka N.
    Heilbrun, Lance K.
    Monk, Paul, III
    Tejwani, Sheela
    Sonpavde, Guru
    Hwang, Clara
    Smith, Daryn
    Jasti, Pallavi
    Dobson, Kimberlee
    Dickow, Brenda
    Heath, Elisabeth I.
    Semaan, Louie
    Cher, Michael L.
    Fontana, Joseph A.
    Chinni, Sreenivasa
    JAMA NETWORK OPEN, 2021, 4 (01) : E2034633
  • [30] Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial.
    Smith, Matthew Raymond
    Hussain, Maha H. A.
    Saad, Fred
    Fizazi, Karim
    Sternberg, Cora N.
    Crawford, E. David
    Kopyltsov, Evgeny
    Park, Chandler H.
    Alexeev, Boris
    Montesa, Alvaro
    Ye, Dingwei
    Parnis, Francis
    Cruz, Felipe Melo
    Tammela, Teuvo
    Suzuki, Hiroyoshi
    Joensuu, Heikki
    Thiele, Silke
    Li, Rui
    Kuss, Iris
    Tombal, Bertrand F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345